LiquidCell™

Non-invasive, negative enrichment system for depletion of white blood cells (WBCs) and enumeration and retrieval of circulating rare cells (CRCs)

Abnova’s LiquidCell™ is a non-invasive, negative enrichment system for depletion of white blood cells (WBCs) and enumeration and retrieval of circulating rare cells (CRCs). Three major subtypes of CRCs in translational research and clinical studies are circulating cells (CTCs), circulating progenitor cells (CPCs), and circulating fetal cells (CFCs). A challenge for market adoption of CRCs is the efficient and reproducible identification, single cell isolation and retrieval of highly pure and viable CRCs, with their applications supported by a wide repertoire of standardized, GMP bioreagents.


LiquidCell™ platform utilizes high efficiency AbBeads™, a cell recovery SuperSlide™, and signal amplification TYRx™ bioreagents to enable CRC isolation and detection. AbBeads™ are antibody functionalized magnetic beads for non-aggregating WBC depletion while minimizing the concomitant loss of CRCs. SuperSlide™ is a specialty-coated, non-autofluorescent glass slide for maximal CRC recovery and precise identification of the non-depleted cell fraction representing the largest pool of unbiased CRCs. TYRx™ are tyramide fluorescence which utilizes HRP-conjugated secondary antibody to provide the highest signal detection of albeit low-density proteins expressed by the evolving CRCs.


Monoclonal antibodies targeting the intracellular and cell surface proteins can be flexibly interchanged to accommodate the biomarker switch in disease progression. This results in highly pure and viable CRCs for downstream protein characterizations, gene analysis, and cell assays. CTC enumeration is currently the only FDA approved application as a prognostic marker in metastatic breast, prostate, and colorectal cancers. In contrast, effective single cell isolation and retrieval of CRCs will open up new clinical utilities in the diagnostic and pharmaceutical arena.



Subtypes of CRCs

 

  • Circulating Tumor Cells (CTCs)
  • Circulating Progenitor Cells (CPCs)
  • Circulating Fetal Cells (CFCs)


Applications of CTCs

 

Protein characterizations

  • Immunofluorescence (IF)
  • Immunocytochemistry (ICC)

Gene analysis

  • Fluorescent In Situ Hybridization (FISH)
  • Polymerase Chain Reaction (PCR)
  • Comparative Genomic Hybridization (CGH)
  • Next Generation Sequencing (NGS)

Cell assays

  • Primary cell line construction
  • Compound screening


Advantages of LiquidCell™ Platform

 

  • Non-destructive and non-aggregating
    removal of WBCs
  • Minimal concomitant cell loss during WBC depletion
  • Maximal cell recovery for downstream identification
  • Maximal signal detection of low-density biomarkers

LiquidCell™ Platform

 

 

 

©2017 Abnova Diagnostics. All rights reserved.

粤公网安备 44190002001574号